Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:19:38 EDT Sun 07 Jun 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:CYTK from 2025-06-06 to 2026-06-05 - 59 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-06-01 07:30U:CYTKNews ReleaseCytokinetics Launches MYQORZO(TM) (aficamten) in European Union, with First Commercial Availability in Germany
2026-05-27 16:00U:CYTKNews ReleaseCytokinetics to Participate in June Investor Conferences
2026-05-20 16:00U:CYTKNews ReleaseCytokinetics to Hold Annual Meeting of Stockholders
2026-05-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-05-14 07:30U:CYTKNews ReleaseCytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
2026-05-12 16:00U:CYTKNews ReleaseCytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-11 10:06U:CYTKNews ReleaseCytokinetics Announces New Data Related to MYQORZO(TM) (aficamten) at ESC Heart Failure 2026
2026-05-08 10:52U:CYTKNews ReleaseCytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million
2026-05-06 23:00U:CYTKNews ReleaseCytokinetics Announces Pricing of Upsized Public Offering of Common Stock
2026-05-05 16:15U:CYTKNews ReleaseCytokinetics Announces Proposed Public Offering of Common Stock
2026-05-05 16:05U:CYTKNews ReleaseCytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 07:30U:CYTKNews ReleaseCytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
2026-05-04 16:00U:CYTKNews ReleaseCytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
2026-04-28 07:30U:CYTKNews ReleaseCytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
2026-04-21 16:00U:CYTKNews ReleaseCytokinetics to Announce First Quarter Results on May 5, 2026
2026-04-20 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-04-06 16:00U:CYTKNews ReleaseCytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-03-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-03-16 08:00U:CYTKNews ReleaseCytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
2026-03-02 16:00U:CYTKNews ReleaseCytokinetics to Participate in March Investor Conferences
2026-02-24 16:00U:CYTKNews ReleaseCytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
2026-02-17 07:30U:CYTKNews ReleaseCytokinetics Announces European Commission Approval of MYQORZO(TM) (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-02-12 16:00U:CYTKNews ReleaseCytokinetics to Announce Fourth Quarter Results on February 24, 2026
2026-02-09 07:30U:CYTKNews ReleaseCytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
2026-01-27 08:00U:CYTKNews ReleaseCytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
2026-01-27 07:30U:CYTKNews ReleaseCytokinetics Announces MYQORZO(TM) (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2026-01-20 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-05 16:00U:CYTKNews ReleaseCytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-19 16:00U:CYTKNews ReleaseCytokinetics Announces FDA Approval of MYQORZO(TM) (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2025-12-17 07:30U:CYTKNews ReleaseCytokinetics Announces NMPA Approval of MYQORZO(TM) (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
2025-12-16 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-12-12 08:43U:CYTKNews ReleaseCytokinetics Announces Positive CHMP Opinion of MYQORZO(TM) (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
2025-11-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-11-17 08:10U:CYTKNews ReleaseCytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
2025-11-10 07:30U:CYTKNews ReleaseCytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
2025-11-05 16:00U:CYTKNews ReleaseCytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-04 16:00U:CYTKNews ReleaseCytokinetics to Participate in November Investor Conferences
2025-10-31 07:30U:CYTKNews ReleaseCytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
2025-10-22 16:00U:CYTKNews ReleaseCytokinetics to Announce Third Quarter Results on November 5, 2025
2025-10-17 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-09-29 07:31U:CYTKNews ReleaseCytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
2025-09-24 07:30U:CYTKNews ReleaseCytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
2025-09-23 16:00U:CYTKNews ReleaseCytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
2025-09-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-09-18 07:30U:CYTKNews ReleaseCytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
2025-09-16 23:46U:CYTKNews ReleaseCytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
2025-09-16 16:02U:CYTKNews ReleaseCytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
2025-08-31 12:10U:CYTKNews ReleaseCytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
2025-08-30 03:18U:CYTKNews ReleaseCytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
2025-08-27 16:00U:CYTKNews ReleaseCytokinetics to Participate in September Investor Conferences
2025-08-25 07:30U:CYTKNews ReleaseCytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
2025-08-20 07:30U:CYTKNews ReleaseCytokinetics Names Jim Daly to Board of Directors
2025-08-19 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-07 16:00U:CYTKNews ReleaseCytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-24 16:00U:CYTKNews ReleaseCytokinetics to Announce Second Quarter Results On August 7, 2025
2025-07-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-07-10 07:30U:CYTKNews ReleaseCytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
2025-06-17 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-10 07:30U:CYTKNews ReleaseCytokinetics Announces Call For Proposals For Annual Corporate Giving Program